Scarica l'app Stockscreener
0.1882
0.00%
0.00
Coeptis Therapeutics Holdings Inc Borsa (COEP) Ultime notizie
Coeptis Therapeutics progresses in cell therapy trials - Investing.com
Coeptis Therapeutics progresses in cell therapy trials - Investing.com India
Coeptis Therapeutics progresses in cell therapy trials By Investing.com - Investing.com UK
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - Nasdaq
Coeptis Therapeutics (NASDAQ:COEP) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS - Defense World
Coeptis Therapeutics to Present at the Emerging Growth Conferenc - GuruFocus.com
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Growth in Short Interest - Defense World
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - Longview News-Journal
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting - Longview News-Journal
Coeptis Therapeutics retracts financial statements due to errors - Investing.com
Daily Progress: Coeptis Therapeutics Holdings Inc (COEP) Drop -0.88, Closing at 0.20 - The Dwinnex
Holdings of Coeptis Therapeutics Holdings Inc (COEP) are aligned with the stars - SETE News
Riding the Waves: A Guide to Investing in COEP Stock - The InvestChronicle
Was anything negative for Coeptis Therapeutics Holdings Inc (COEP) stock last session? - US Post News
Market Insight: Coeptis Therapeutics Holdings Inc (COEP)’s Notable Drop, Closing at 0.24 - The Dwinnex
Critical Survey: Vir Biotechnology (NASDAQ:VIR) & Coeptis Therapeutics (NASDAQ:COEP) - Defense World
A Guide To The Risks Of Investing In Coeptis Therapeutics Holdings Inc (COEP) – Knox Daily - Knox Daily
LADENBURG THALM/SH SH Lowers Coeptis Therapeutics (NASDAQ:COEP) to Hold - Defense World
Coeptis Therapeutics Closes $4.3 Million Series A - citybiz
Coeptis Therapeutics Closes $4.3M Series A Funding - FinSMEs
Coeptis Therapeutics closes on $4.3 million Series APittsburgh Business Times - The Business Journals
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering - Quantisnow
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering - Quantisnow
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer - Quantisnow
Coeptis Therapeutics to Present at the Emerging Growth Conference - Quantisnow
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for ... - Quantisnow
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PR Newswire
COEP’s Stochastic Averages Dip: Analyzing Coeptis Therapeutics Holdings Inc’s Stock Performance - The InvestChronicle
Coeptis Therapeutics Holdings Inc (COEP) presents a great opportunity, but the stock is slightly overvalued – US Post ... - US Post News
Coeptis Therapeutics Holdings Inc's latest rating changes from various analysts – Knox Daily - Knox Daily
Head to Head Analysis: DBV Technologies (NASDAQ:DBVT) & Coeptis Therapeutics (NASDAQ:COEP) - Defense World
Is Coeptis Therapeutics Holdings Inc (COEP) positioned for future growth? – Sete News - SETE News
Coeptis Therapeutics Holdings Inc (COEP) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - Marketscreener.com
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - PR Newswire
Coeptis Therapeutics Holdings Inc (COEP) Clearly Signals Buy-Into the Stock: Don't ignore the signals – Sete News - SETE News
Market Momentum: Coeptis Therapeutics Holdings Inc (COEP) Registers a 10.19 Increase, Closing at 0.29 – DWinneX - The Dwinnex
The time has not yet come to remove your chips from the table: Coeptis Therapeutics Holdings Inc (COEP) – Sete News - SETE News
Financial Metrics Exploration: Understanding Coeptis Therapeutics Holdings Inc (COEP) Through Ratios – DWinneX - The Dwinnex
Coeptis Therapeutics Holdings Inc [COEP] stock for 1305 USD was acquired by DeSilva Tara – Knox Daily - Knox Daily
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 10.6% - Defense World
A Tale of Resilience: Coeptis Therapeutics Holdings Inc Amid Stock Market Turbulence - The InvestChronicle
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - Nasdaq
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - PR Newswire
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th ... - PR Newswire
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting - PR Newswire
Coeptis Therapeutics' Dave Mehalick on Making Cell Therapy Universally AccessibleInvestorNews - InvestorNews Inc.
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 ... - InvestorNews Inc.
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK - PR Newswire
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections - PR Newswire
Coeptis Therapeutics Risks Nasdaq Delisting Over Price - TipRanks
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 - PR Newswire
Coeptis Therapeutics to Present at the Emerging Growth Conference - Yahoo Finance
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 - PR Newswire
Coeptis Therapeutics Announces $2 Million Private Placement - PR Newswire
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology - PR Newswire
Coeptis Therapeutics Could Revolutionize The Treatment of Cancer - Small Cap Exclusive
Biotech Stocks Take Centerstage as Markets Turn Red (COEP,AMLX, BMRN, EXEL, HALO, INVA, MDXG, INCY, JAZZ ... - BP Journal
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection - PR Newswire
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment - PR Newswire
Coeptis appoints Colleen Delaney as chief scientific and medical officerPittsburgh Business Times - The Business Journals
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer - PR Newswire
Coeptis licenses Deverra Therapeutics' clinical stage assets - Pharmaceutical Technology
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics - PR Newswire
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic - PR Newswire
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering - PR Newswire
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering - BioSpace
Coeptis Therapeutics Could Go To The Moon This Week! - Small Cap Exclusive
Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer - citybiz
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics - PR Newswire
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies - PR Newswire
Biodexa Pharmaceuticals Stock (NASDAQ:BDRX), Quotes and News Summary - Benzinga
Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today? - InvestorPlace
1.25%
1.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):